Money
Filter News
Found 82,931 articles
-
In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030.
-
ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies
12/7/2023
ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), today announced the closing of an oversubscribed and upsized $90 million Series A financing co-led by Third Rock Ventures and an undisclosed healthcare fund.
-
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
12/7/2023
ZyVersa Therapeutics, Inc. announced the pricing of a “reasonable best efforts” public offering of 4,000,000 shares of common stock and accompanying Series A and Series B warrants to purchase up to an aggregate of 8,000,000 shares of common stock at a combined public offering price of $1.25, resulting in gross proceeds of approximately $5.0 million.
-
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
12/7/2023
Exact Sciences announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program.
-
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
12/7/2023
Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.
-
Justera Announces 2023 AGM Results
12/7/2023
Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") announces the voting results from the Annual General and Special Meeting of Shareholders (the "Meeting") which was held on December 6, 2023.
-
Fueled partly by increasing lifespans and cancer incidence, the area’s worth is projected to soar to 13.67 billion by 2032, Precedence Research reports.
-
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
12/6/2023
ImmunoPrecise Antibodies Ltd. announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share.
-
Microbix Announces Initiation of Normal Course Issuer Bid
12/6/2023
Microbix Biosystems Inc. announces the initiation of a Normal Course Issuer Bid program for the repurchase and cancellation of outstanding common shares.
-
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement - December 06, 2023
12/6/2023
Cardio Diagnostics Holdings, Inc. announced that on December 5, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
-
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
12/6/2023
Kamada Ltd. announced the execution of a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB® U.S. distribution agreement between the parties.
-
West Announces First-Quarter 2024 Dividend
12/6/2023
West Pharmaceutical Services, Inc. announced that the Company's Board of Directors has approved a first-quarter 2024 dividend of $0.20 per share.
-
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
12/6/2023
LTS, a leading pharmaceutical technology company, announced that it has received a grant from the Bill & Melinda Gates Foundation.
-
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering - December 06, 2023
12/6/2023
EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share.
-
Adcentrx Announces Extension of Series A+ Financing to $51 Million
12/6/2023
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 06, 2023
12/6/2023
Apellis Pharmaceuticals, Inc., announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/6/2023
BIOLASE, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules.
-
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - December 06, 2023
12/6/2023
89bio, Inc. announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.
-
BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024
12/6/2023
BioSig Technologies, Inc., a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, issued its 2023 letter to shareholders to recap recent achievements and offer insights about the year ahead.
-
Bristol Myers Squibb Announces Dividend Increase - December 06, 2023
12/6/2023
Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of sixty cents per share on the $0.10 par value common stock of the company.